Basket Study at Providence Medical Group
Providence Medical Group is currently enrolling patients for the following
basket studies:
Aadi TSC-007
Treatment agent: Nab-sirolimus- a novel human albumin-bound form of sirolimus
(rapamycin)
Physician:
Ian Anderson, MD
Study Coordinator: Camille Shaffer //
camille.shaffer@stjoe.org // 707-521-3830
Study Resources:
Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid
Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1) -
Full Text View - ClinicalTrials.gov
Sponsor: Aadi Bioscience
Location: Providence Cancer Center Santa Rosa, CA
Study to test a new drug in participants with advanced or metastatic ovarian,
endometrial or HER2-breast cancer
Treatment agent: AZD8205- a B7-H4 targeted antibody drug conjugate (ADC).
Physician:
Ian Anderson, MD
Study Coordinator: Camille Shaffer //
camille.shaffer@stjoe.org // 707-521-3830
Study Resources:
First in Human Study to Evaluate AZD8205 in Patients With Advanced or Metastatic
Solid Malignancies - Full Text View - ClinicalTrials.gov
Sponsor: AstraZeneca
Location: Providence Cancer Center Santa Rosa, CA
A study of Dato-Dxd as monotherapy and in combination with anti-cancer
agents in patients with advanced solid tumors: AZ D926UC00001 Tropion
Pan-Tumor 03.
Treatment agent: Datopotamab Deruxtecan- an ADC comprised of a recombinant
humanized anti-TROP2 IgG1 mAb
Physician:
Yao Yao Pollock, MD
Study Coordinator: Camille Shaffer //
camille.shaffer@stjoe.org // 707-521-3830
Study Resources:
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents
in Patients With Advanced Solid Tumours (TROPION-PanTumor03) - Full Text
View - ClinicalTrials.gov
Sponsor: AstraZeneca
Location: Providence Cancer Center Santa Rosa, CA
A study for patients with advanced solid tumors with MTAP inhibitor
Treatment agent: IDE397 as a single agent and in combination with docetaxel,
paclitaxel, gemcitabine/nab-paclitaxel and pemetrexed
Physician:
Ian Anderson, MD
Study Coordinator: Teresa Lund //
teresa.lund@stjoe.org // 707-521-3830
Study Resources:
Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion
- Full Text View - ClinicalTrials.gov
Sponsor: IDEAYA Biosciences
Location: Providence Cancer Center Santa Rosa, CA
A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express
HER2 (SGN005)
Treatment agent: Disitamab Vedotin, antibody-drug conjugate targeting human
epidermal growth factor receptor 2 (HER2)
Physician:
Ian Anderson, MD
Study Coordinator: Teresa Lund //
teresa.lund@stjoe.org // 707-521-3830
Study Resources:
https://classic.clinicaltrials.gov/ct2/show/NCT06003231
Sponsor: Seagen Inc.
Location: Providence Cancer Center Santa Rosa, CA
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors
Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)
Treatment agent: Repotrectinib (TPX-0005) oral medication
Physician:
Ian Anderson, MD
Study Coordinator: Tracy Foster //
tracy.foster@stjoe.org // 707-521-3830
Study Resources:
https://www.clinicaltrials.gov/study/NCT03093116
Sponsor: Turning Point Therapeutics, Inc.
Location: Providence Cancer Center Santa Rosa, CA
Phase 1/2 Study of PRO1184 in Patients with Locally Advanced and/or Metastatic
Solid Tumors (PRO1184-001)
Treatment agent: PRO1184, a folate receptor alpha (FRα) targeted
antibody-drug conjugate
Physician:
Ian Anderson, MD
Study Coordinator: Tracy Foster //
tracy.foster@stjoe.org // 707-521-3830
Study Resources:
https://clinicaltrials.gov/study/NCT05579366
Sponsor: ProfoundBio / Precision for Medicine
Location: Providence Cancer Center Santa Rosa, CA
A Phase 1/2 Dose Escalation/Expansion Study of NGM707 as Monotherapy and
in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor
Malignancies
Treatment agent: NGM707 +/- Pembrolizumab
Physician:
Ian Anderson, MD
Study Coordinator: Melissa Ulrich //
melissa.ulrich@providence.org // 707-521-3830
Study Resources:
https://clinicaltrials.gov/study/NCT04913337
Sponsor: NGM Biopharmaceuticals, Inc
Location: Providence Cancer Center Santa Rosa, CA